Study identifier:1839IL/0547
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Phase II study of Iressa with/without concurrent chemoradiotherapy in patients with advanced non-nasopharyngeal head and neck carcinoma and to study the effect of Iressa™ (ZD1839) on tumour gene expression profiles ®
head and neck cancer
Phase 2
No
Gefitinib
All
60
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Dec 2007 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|